Business
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
CPT codes are critical to receiving reimbursement from federal and private payers CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq:
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":"\nCPT codes are critical to receiving reimbursement from federal and private payers\n\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT Proprietary Laboratory Analyses (PLA) codes. If approved, the codes are expected to be published by the AMA by January 1, 2024, and will be effective on April 1, 2024. Obtaining CPT PLA codes would be a significant step towards securing federal and private payer reimbursement for the Epi+Gen CHD and PrecisionCHD tests.\n\n\nPrecisionCHD is the first artificial intelligence-driven integrated epigenetic-genetic diagnostic blood test for coronary heart disease, and Epi+Gen CHD is the first artificial intelligence-driven integrated epigenetic-genetic blood test to evaluate the three-year risk of a heart attack. Dedicated CPT PLA codes would ensure that the tests are properly identified when submitting claims to payers, streamlining the reimbursement process.\n\n\nThe CPT coding system provides a standardized terminology for physicians and other healthcare professionals to code medical services and procedures in the United States. CPT codes represent the most universally utilized medical terminology for reporting medical services to public and private health insurance payers. This includes coding for laboratory tests, physician services, and services from other healthcare professionals. The use of CPT codes offers a common language for reporting and billing various medical services across the American healthcare system.\n\n\nMeesha Dogan PhD, CEO and Co-Founder of Cardio Diagnostics noted that \"pursuing CPT PLA codes is a key step in ensuring that more Americans can access Cardio’s next-generation cardiovascular tests, facilitating broader adoption of our tests.”\n\n\nAbout Cardio Diagnostics\n\n\nCardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial ...